Clarus Corp: Why CLAR Is Languishing At A Sub-$100M EV
Clarus's enterprise value is under $100 million, but its brands could privately sell for $300-$500 million, implying a stock ...
Strong Buy Rating for Black Diamond Therapeutics Driven by Financial Stability and Promising Clinical Developments
Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Black Diamond Therapeutics (BDTX – Research Report), retaining the ...
Black Diamond: Q3 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Black Diamond Therapeutics, Inc. (BDTX) on Tuesday reported a loss of $15.6 million in its third quarter. The Cambridge, Massachusetts-based company ...
Promising Clinical Outcomes and Financial Stability Support Buy Rating for Black Diamond Therapeutics
TD Cowen analyst Marc Frahm has maintained their bullish stance on BDTX stock, giving a Buy rating today. Marc Frahm’s rating is based ...